<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Eyepoint Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc</link>
<description>Latest news and press releases for Eyepoint Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/eyepoint-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683565b978dffbe2df0f0322.webp</url>
<title>Eyepoint Pharmaceuticals Inc</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc</link>
</image>
<item>
<title>EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-to-report-first-quarter-2026-financial-results-on-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-to-report-first-quarter-2026-financial-results-on-may-6-2026</guid>
<pubDate>Wed, 29 Apr 2026 11:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conf</description>
</item>
<item>
<title>EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-corporate-developments-7</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-corporate-developments-7</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3</description>
</item>
<item>
<title>EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-first-patients-dosed-in-both-global-phase-3-clinical-trials-of-duravyutm-for-the-treatment-of-diabetic-macular-edema</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-first-patients-dosed-in-both-global-phase-3-clinical-trials-of-duravyutm-for-the-treatment-of-diabetic-macular-edema</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME</description>
</item>
<item>
<title>EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-4-2026</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative</description>
</item>
<item>
<title>EyePoint Appoints Michael Campbell as Chief Commercial Officer</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-appoints-michael-campbell-as-chief-commercial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-appoints-michael-campbell-as-chief-commercial-officer</guid>
<pubDate>Wed, 18 Feb 2026 12:00:00 GMT</pubDate>
<description>– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma –– Brings established track record of successful product launches and oversight of prominent ophthalmology franchises, including Lucentis® and Xiidra® – WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today</description>
</item>
<item>
<title>EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-05</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02-05</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative</description>
</item>
<item>
<title>EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-01-16</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-01-16</guid>
<pubDate>Fri, 16 Jan 2026 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help</description>
</item>
<item>
<title>EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-corporate-update-and-anticipated-pivotal-milestones-2026-2026-01-07</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-corporate-update-and-anticipated-pivotal-milestones-2026-2026-01-07</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on</description>
</item>
<item>
<title>EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative</description>
</item>
<item>
<title>EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-positive-recommendation-independent-data-safety-monitoring</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-positive-recommendation-independent-data-safety-monitoring</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous</description>
</item>
<item>
<title>EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-third-quarter-2025-financial-results-and-highlights-recent-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-third-quarter-2025-financial-results-and-highlights-recent-corporate</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation</description>
</item>
<item>
<title>EyePoint Announces Participation at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-participation-upcoming-investor-conferences-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-participation-upcoming-investor-conferences-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing</description>
</item>
<item>
<title>EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-report-third-quarter-2025-financial-results-november-5-2025-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-report-third-quarter-2025-financial-results-november-5-2025-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing</description>
</item>
<item>
<title>EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-pivotal-phase-3-program-initiation-duravyutm-diabetic-macular</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-pivotal-phase-3-program-initiation-duravyutm-diabetic-macular</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME</description>
</item>
<item>
<title>EyePoint Announces Pricing of Public Offering</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-pricing-public-offering-2025-10-15</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-pricing-public-offering-2025-10-15</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing</description>
</item>
<item>
<title>EyePoint Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-proposed-public-offering-common-stock-2025-10-14</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-announces-proposed-public-offering-common-stock-2025-10-14</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing</description>
</item>
<item>
<title>EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-second-quarter-2025-110000781</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-reports-second-quarter-2025-110000781</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securit</description>
</item>
<item>
<title>EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-present-hc-wainwright-5th-annual-ophthalmology-virtual-conference-2025-08-06</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-present-hc-wainwright-5th-annual-ophthalmology-virtual-conference-2025-08-06</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing</description>
</item>
<item>
<title>EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-report-second-quarter-2025-financial-results-august-6-2025-2025-07-30</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-report-second-quarter-2025-financial-results-august-6-2025-2025-07-30</guid>
<pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing</description>
</item>
<item>
<title>EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-completes-enrollment-pivotal-phase-3-trials-duravyutm-wet-age-related</link>
<guid isPermaLink="true">https://6ix.com/company/eyepoint-pharmaceuticals-inc/news/eyepoint-completes-enrollment-pivotal-phase-3-trials-duravyutm-wet-age-related</guid>
<pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
<description>– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal</description>
</item>
</channel>
</rss>